Empagliflozin in Diuretic Refractory Ascites (DRAin-Em 01)
Management of Diuretic Refractory Ascites in Cirrhosis With Empagliflozin (DRAin-Em-01)
Sponsor: Stanford University
A PHASE1 clinical study on Ascites and Ascites Hepatic, this trial is completed. The trial is conducted by Stanford University and has accumulated 8 data snapshots since 2021. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
8 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE1
-
Sep 2023 — Jul 2024 [monthly]
Completed PHASE1
Status: Active Not Recruiting → Completed
-
May 2023 — Sep 2023 [monthly]
Active Not Recruiting PHASE1
Status: Recruiting → Active Not Recruiting
-
Nov 2022 — May 2023 [monthly]
Recruiting PHASE1
▶ Show 3 earlier versions
-
Apr 2022 — Nov 2022 [monthly]
Recruiting PHASE1
Status: Not Yet Recruiting → Recruiting
-
Dec 2021 — Apr 2022 [monthly]
Not Yet Recruiting PHASE1
-
Sep 2021 — Dec 2021 [monthly]
Not Yet Recruiting PHASE1
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Stanford University
For direct contact, visit the study record on ClinicalTrials.gov .